Dr. Tarek M. Sabagh
Claim this profileMiami Valley Hospital South
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
71 reported clinical trials
126 drugs studied
About Tarek M. Sabagh
Education:
- Obtained a Medical degree (MD) from the American University of Beirut Faculty of Medicine, Lebanon, in 2007.
- Completed Residency in Internal Medicine at the University of Cincinnati Medical Center, Ohio (2008-2011).
- Undertook a Fellowship in Gastroenterology and Hepatology at the University of Cincinnati Medical Center, Ohio (2011-2014).
Experience:
- Currently practices as a gastroenterologist at Miami Valley Hospital South.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Tarek M. Sabagh is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Tarek M. Sabagh
Clinical Trial Related2 years of experience running clinical trials · Led 71 trials as a Principal Investigator · 38 Active Clinical TrialsTreatments Tarek M. Sabagh has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Cisplatin
- Ipilimumab
- Atezolizumab
Breakdown of trials Tarek M. Sabagh has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tarek M. Sabagh specialize in?
Tarek M. Sabagh focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Tarek M. Sabagh currently recruiting for clinical trials?
Yes, Tarek M. Sabagh is currently recruiting for 38 clinical trials in Centerville Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tarek M. Sabagh has studied deeply?
Yes, Tarek M. Sabagh has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Tarek M. Sabagh?
Apply for one of the trials that Tarek M. Sabagh is conducting.
What is the office address of Tarek M. Sabagh?
The office of Tarek M. Sabagh is located at: Miami Valley Hospital South, Centerville, Ohio 45459 United States. This is the address for their practice at the Miami Valley Hospital South.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.